New anthracycline derivatives: What for?
- 1 December 1991
- journal article
- review article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (12) , 1542-1544
- https://doi.org/10.1016/0277-5379(91)90409-7
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patientsEuropean Journal of Cancer and Clinical Oncology, 1990
- 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistanceEuropean Journal of Cancer and Clinical Oncology, 1990
- Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicityPharmacology & Therapeutics, 1990
- Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast CancerNew England Journal of Medicine, 1988
- Multiple-Drug Resistance in Human CancerNew England Journal of Medicine, 1987
- A Chemical Perspective on the Anthracycline Antitumor AntibioticsEnvironmental Health Perspectives, 1985
- Dissociation of Antitumor Potency from Anthracycline Cardiotoxicity in a Doxorubicin AnalogScience, 1985
- Oxygen-Derived Free Radicals in Postischemic Tissue InjuryNew England Journal of Medicine, 1985
- Intensely potent morpholinyl anthracyclinesJournal of Medicinal Chemistry, 1984
- Antitumor anthracyclines: Recent developmentsMedicinal Research Reviews, 1984